Horizon will help develop the cell line-derived reference material, St. George's will provide clinical samples, and the EMQN will run a validation study.
The partners are planning to integrate the technology into Horizon's research tools and services and to develop it for applications in cell therapeutics.
The firm said it saw a robust contribution in the first half of the year from its Dharmacon business and noted that it increased its reach into the US market.
After acquiring Dharmacon, as well as licensing a wide array of editing technologies, Horizon has built itself into a repository of knowledge and tools.
The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.
In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.
The company said its product revenues for the year rose 101 percent while its services revenues rose 7 percent.
The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.
Horizon will develop NTRK fusion immunohistochemistry reference standards to be used in oncology assays.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.